#### The bottom line Behavioural and psychological symptoms of dementia such as agitation and aggression are commonly treated with atypical antipsychotic drugs, which are associated with severe side effects.1 However, there is increasing evidence of potential harms associated with use of these drugs in people with dementia, and guidelines increasingly recommend restricting their use. In Europe, only risperidone is currently licensed for use in dementia and only for up to six weeks in patients with severe aggression, defined as causing risk or severe distress, which has not responded to other treatments. No antipsychotics are approved for this patient group in the United States. Best practice guidelines, including National Institute for Health and Care Excellence guidelines in the United Kingdom and American Psychiatric Association guidelines in the US, are similar. However, they do not distinguish between individual atypical antipsychotics and recommend a maximum treatment period of 12 weeks, except in exceptional circumstances.2 3 #### Sources and selection criteria This article is based on an updated review of the literature published in systematic reviews. We searched the electronic databases PubMed, Embase, and the Cochrane Library. We evaluated individual randomised controlled trials from systematic reviews to calculate the specific attributable risk of key adverse events associated with risperidone in people with Alzheimer’s disease. Studies were selected according to the …
No takes yet. Share an insight, caveat, or question.
Corbett et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: